Comparison of J5 vaccinates and controls for incidence, etiologic agent, clinical severity, and survival in the herd following naturally occurring cases of clinical mastitis

被引:38
作者
Wilson, D. J. [1 ]
Grohn, Y. T.
Bennett, G. J.
Gonzalez, R. N.
Schukken, Y. H.
Spatz, J.
机构
[1] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84321 USA
[2] Cornell Univ, Dept Populat Med & Diag Sci, Ithaca, NY 14850 USA
[3] Ctr Anim Hlth, Te Aroha 3320, New Zealand
关键词
clinical mastitis; bovine mastitis; dairy cattle; immunology;
D O I
10.3168/jds.2007-0160
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
Holstein dairy cattle in 3 commercial herds were randomly allocated to J5 vaccination (n = 251) or untreated control (n = 306) groups. There were 221 new cases of clinical mastitis (CM) affecting 120 cows. Coliform mastitis cases had a higher percentage of severe quarter swelling or signs of systemic illness among control cows but not among J5 vaccinates, in comparison to noncoliform cases. Culling or death from CM affected 13 controls (4.3%) and 4 vaccinates (1.6%), with losses occurring earlier in lactation among controls, a higher hazard (probability of a cow dying on each day of lactation) for controls than vaccinates. The J5 vaccination was significantly associated with protection from culling for mastitis among the 15 Klebsiella cases; 2 out of 10 (20%) Klebsiella-infected controls were culled and 0 out of 5 vaccinates were culled. Cows in second lactation were at reduced hazard of culling for mastitis compared with older animals, even when adjusting for effects of J5 vaccination. When all CM cases (including subsequent new cases during the same lactation and multiple quarters or pathogens within the same cow on the same day) were evaluated, for the 221 cases of CM, the rate was significantly higher among vaccinates than controls (0.10 and 0.07 cases/30 d in milk, respectively). This was because J5 vaccinates had more subsequent new cases of CM in the same cow than controls. Pathogens isolated, which included mainly environmental bacteria, were not different among J5 vaccinates and controls. Immunization with J5 was associated with protection against severe clinical coliform mastitis signs, culling, and death loss from CM but not with any reduction in overall CM.
引用
收藏
页码:4282 / 4288
页数:7
相关论文
共 12 条
[1]   Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis [J].
Cross, AS ;
Opal, SM ;
Warren, HS ;
Palardy, JE ;
Glaser, K ;
Parejo, NA ;
Bhattacharjee, AK .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (07) :1079-1086
[2]  
CULLOR JS, 1991, VET MED-US, V86, P836
[3]   Survival analysis in clinical trials: Past developments and future directions [J].
Fleming, TR ;
Lin, DY .
BIOMETRICS, 2000, 56 (04) :971-983
[4]  
GONZALEZ RN, 1989, CAN J VET RES, V53, P301
[5]  
GONZALEZ RN, 1996, P 19 WORLD BUIATR C, P27
[6]   FIELD TRIAL TO DETERMINE EFFICACY OF AN ESCHERICHIA-COLI J5 MASTITIS VACCINE [J].
HOGAN, JS ;
SMITH, KL ;
TODHUNTER, DA ;
SCHOENBERGER, PS .
JOURNAL OF DAIRY SCIENCE, 1992, 75 (01) :78-84
[7]  
HOGAN JS, 1999, LAB HDB BOVINE MASTI, P85
[8]  
JACKSON ER, 1983, VET RECORD S, V5, P135
[9]   EFFECT OF RE-17 MUTANT SALMONELLA-TYPHIMURIUM BACTERIN TOXOID ON CLINICAL COLIFORM MASTITIS [J].
MCCLURE, AM ;
CHRISTOPHER, EE ;
WOLFF, WA ;
FALES, WH ;
KRAUSE, GF ;
MIRAMONTI, J .
JOURNAL OF DAIRY SCIENCE, 1994, 77 (08) :2272-2280
[10]  
SCOTT HM, 1996, P WORLD ASS BUIATR 1, P281